Loading organizations...
§ Private Profile · Lexington, MA, USA
Biotechnology company developing and manufacturing lentiviral vectors for gene therapy programs using a stable production platform.
iVexSol, based in Lexington, Massachusetts, develops and manufactures lentiviral vectors for gene therapy programs using a proprietary stable production platform. This innovative technology simplifies production, reduces costs and time, and supports clinical development with stable producer cell lines and vector fitness testing. The company has secured $38.8 million in total funding through equity investments, including Series A rounds, and features investors including Casdin Capital, BioLife Solutions, Bristol-Myers Squibb, Asahi Kasei, and Charles River Laboratories. iVexSol provides manufacturing services to biotechnology and pharmaceutical clients. Founded in 2019, with Dr. Greene noted as a co-founder, it employs 10 to 50 individuals. Its business model centers on venture-funded through equity investments, including Series A rounds totaling $38.8M, provides manufacturing services to biotech and pharma.
iVexSol has raised $38.8M across 3 funding rounds.
iVexSol has raised $38.8M in total across 3 funding rounds.
iVexSol has raised $38.8M across 3 funding rounds. Most recently, it raised $23.8M Series A in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 26, 2023 | $23.8M Series A | — | Asahi Kasei Medical, BioLife Solutions, Bristol Myers Squibb, Casdin Capital, Charles River Laboratories | Announced |
| Dec 1, 2020 | $13M Series A | — | BioLife Solutions, Casdin Capital | Announced |
| Oct 1, 2019 | $2M Venture Round | BioLife Solutions, Casdin Capital | — | Announced |
iVexSol has raised $38.8M in total across 3 funding rounds.
iVexSol's investors include Asahi Kasei Medical, BioLife Solutions, Bristol Myers Squibb, Casdin Capital, Charles River Laboratories.